CalciMedica (NASDAQ:CALC) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of CalciMedica (NASDAQ:CALC) to a sell rating in a research note published on Saturday morning.

Other analysts have also issued reports about the stock. UBS Group restated a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Guggenheim began coverage on CalciMedica in a report on Thursday. They set a “buy” rating on the stock. Weiss Ratings lowered CalciMedica from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Finally, HC Wainwright restated a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, CalciMedica has an average rating of “Hold” and a consensus price target of $10.00.

CalciMedica Trading Down 1.8%

NASDAQ:CALC opened at $0.57 on Friday. The company has a 50-day moving average price of $0.78 and a 200-day moving average price of $0.70. CalciMedica has a 12 month low of $0.46 and a 12 month high of $7.20. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 1.67. The stock has a market cap of $19.56 million, a price-to-earnings ratio of -0.42 and a beta of 0.91.

CalciMedica (NASDAQ:CALC) last announced its earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.17). Equities analysts predict that CalciMedica will post -1.05 EPS for the current year.

Insider Buying and Selling at CalciMedica

In other CalciMedica news, Director Fred A. Middleton purchased 248,972 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was bought at an average cost of $0.80 per share, for a total transaction of $199,177.60. Following the purchase, the director directly owned 1,063,272 shares in the company, valued at $850,617.60. The trade was a 30.57% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 28.25% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CalciMedica

Several hedge funds have recently bought and sold shares of CALC. 180 Wealth Advisors LLC grew its holdings in CalciMedica by 297.2% in the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after purchasing an additional 94,650 shares during the period. Boothbay Fund Management LLC purchased a new position in shares of CalciMedica during the fourth quarter valued at approximately $506,000. PVG Asset Management Corp bought a new stake in shares of CalciMedica in the 4th quarter worth approximately $302,000. Renaissance Technologies LLC boosted its position in shares of CalciMedica by 45.0% in the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after purchasing an additional 39,775 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in shares of CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after buying an additional 34,386 shares during the last quarter.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.